ReviewHepatology research : the official journal of the Japan Society of Hepatology2017
Role of thrombospondin 1 in liver diseases.
Review in Hepatology research : the official journal of the Japan Society of Hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 72 citations in OpenAlex.
- Immunomodulatory role and therapeutic potential of thrombospondin-1 during infectious diseases and autoimmunity.BMC biology · 2026Review
- An integrative genomic analysis of angiogenesis in hepatocellular carcinoma: from canonical drivers to emerging biomarkers.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling.JHEP reports : innovation in hepatology · 2025Article
- [Aloe-emodin inhibits scar tissue fibrosis through thrombospondin-1-PI3k-Akt pathway].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2025Article
- Diagnostic and prognostic biomarkers in autoimmune hepatitis-associated cirrhosis: insights into TBil, CD38, IL-22, TSP-1, GAL-3, and Cyc-C.Frontiers in medicine · 2025Article
- CD47: an immunoregulatory nexus in liver and gastrointestinal disorders.eGastroenterology · 2025Review
- Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.Journal of Cancer · 2025Article
- Article
- Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females.Discover oncology · 2024Article
- Article
- Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis.JHEP reports : innovation in hepatology · 2024Article
- Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure.BMC medicine · 2024Article
- Identification of integrated proteomics and transcriptomics signature of alcohol-associated liver disease using machine learning.PLOS digital health · 2024Article
- Microarray-based Detection of Critical Overexpressed Genes in the Progression of Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease: A Protein-protein Interaction Network Analysis.Current medicinal chemistry · 2024Article
- Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms.Journal of clinical and translational hepatology · 2023Review
- Fibrosis-Related Gene Profiling in Liver Biopsies of PiZZ α1-Antitrypsin Children with Different Clinical Courses.International journal of molecular sciences · 2023Article
- Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.Cancer biology & medicine · 2023Review
- Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.Nature communications · 2022Article
- Article
- A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.Archives of toxicology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Thrombospondin 1 (TSP1) is a matricellular glycoprotein that can be secreted by many cell types. Through binding to extracellular proteins and/or cell surface receptors, TSP1 modulates a variety of cellular functions. Since its discovery in 1971, TSP1 has been found to play important roles in multiple biological processes including angiogenesis, apoptosis, latent transforming growth factor-β activation, and immune regulation. Thrombospondin 1 is also involved in regulating many organ functions. However, the role of TSP1 in liver diseases has not been extensively addressed. In this review, we summarize the findings about the possible role that TSP1 plays in chronic liver diseases focusing on non-alcoholic fatty liver diseases, liver fibrosis, and hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.